Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Pulmonary Or Respiratory Drug Delivery Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The market for pulmonary or respiratory drug delivery has experienced robust expansion in recent years. Projected to rise from $75.67 billion in 2025 to $82.23 billion in 2026, it reflects a compound annual growth rate (CAGR) of 8.7%. This historical growth has been driven by factors such as the increasing prevalence of asthma and COPD, the widespread use of inhalers, the expansion of respiratory hospitals, advancements in aerosol technologies, and the broadening of homecare treatment options.
The pulmonary drug delivery market, often referred to as the respiratory drug delivery market, is projected to experience significant growth in the coming years. By 2030, its value is anticipated to reach $114.23 billion, reflecting a compound annual growth rate (CAGR) of 8.6%. This expansion during the forecast period is driven by several key factors, including an aging population, increased exposure to air pollution, the rise of digital inhalers, the growing prevalence of homecare settings, and a higher incidence of chronic respiratory conditions. Notable trends shaping this period involve the heightened adoption of inhalation-based drug delivery methods, a surge in demand for respiratory therapies administered at home, increased utilization of dry powder and metered dose inhalers, the broadening of chronic disease management programs for respiratory issues, and a stronger emphasis on developing user-friendly delivery devices.
Download A Free Sample Report For Comprehensive Market Insights:
Pulmonary Or Respiratory Drug Delivery Market Growth Drivers: What Factors Are Accelerating Expansion?
The anticipated growth of the pulmonary or respiratory drug delivery market is being driven forward by the rising incidence of pneumonia. This lung infection triggers inflammation in the air sacs, which can become filled with fluid or pus, resulting in symptoms such as coughing, fever, and breathing difficulties. Factors contributing to the growing prevalence of pneumonia include aging populations, compromised immune systems, respiratory infections, air pollution, smoking, and the emergence of antibiotic-resistant bacteria. By delivering medications like antibiotics, bronchodilators, or anti-inflammatory agents directly to the lungs, pulmonary or respiratory drug delivery offers pneumonia patients faster and more effective treatment, helping to alleviate symptoms, reduce inflammation, clear infections, and enhance respiratory function, which ultimately supports recovery and prevents complications. For example, data from Clinical Trials Arena, a UK-based clinical research news platform, showed that in December 2024, hospital admissions for Mycoplasma pneumoniae surged by 461% between October 2023 and February 2024, climbing from 110 to 617 admissions. Among these, 20.2% of pneumonia cases were found in children aged 0 to 4 years, 25.4% in those aged 5 to 9 years, and 17.5% in children aged 10 to 14 years, accounting for 410 of the 650 reported cases. Consequently, the increasing prevalence of pneumonia is fueling the expansion of the pulmonary or respiratory drug delivery market.
Pulmonary Or Respiratory Drug Delivery Market Segment Analysis And Revenue Opportunities
The pulmonary or respiratory drug delivery market covered in this report is segmented –
1) By Product: Formulation Type, Device Type
2) By Canister Type: Plain Canister, Coated Canister
3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications
4) By End-User: Hospitals, Clinics, Home Care Settings
Subsegments:
1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays
2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices
Pulmonary Or Respiratory Drug Delivery Market Trends: What Is Shaping Future Industry Growth?
Key players in the pulmonary and respiratory drug delivery sector are placing significant emphasis on technological innovations, particularly through the development of complex drug delivery systems designed to improve both treatment effectiveness and patient adherence. These advanced systems facilitate targeted drug delivery and controlled release of therapeutic compounds, thereby enhancing clinical outcomes. A notable example occurred in July 2023, when Viatris Inc., a U.S.-based manufacturer of generic and branded pharmaceuticals, collaborated with Kindeva Drug Delivery L.P., a U.S. drug delivery firm, to introduce Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. This product received approval from the Food and Drug Administration, a U.S. regulatory agency, and represents the first generic alternative to AstraZeneca’s Symbicort. It functions as a metered-dose inhaler combining budesonide and formoterol for the management of asthma and chronic obstructive pulmonary disease, and is offered in two dosage strengths: 80 micrograms with 4.5 micrograms of formoterol, and 160 micrograms with 4.5 micrograms of formoterol.
Pulmonary Or Respiratory Drug Delivery Market Leading Players Shaping Industry Direction
Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc
Access The Complete Pulmonary Or Respiratory Drug Delivery Market Report:
Pulmonary Or Respiratory Drug Delivery Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the pulmonary or respiratory drug delivery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model